<DOC>
	<DOCNO>NCT01251627</DOCNO>
	<brief_summary>The study aim assess activity decitabine treatment CMML .</brief_summary>
	<brief_title>Multicenter Study Assess Efficacy Decitabine Treatment Chronic Myelomonocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>1 . Patients age 18 old 2 . CMML diagnosis accord WHO criteria 3 . If WBC &lt; =12000/mm3 : IPSS High INT2 If WBC &gt; 12000/mm3 : least two follow criterion : Blast cell &gt; 5 % bone marrow Citogenetic abnormality ( 5 ; 12 ) ( q33 ; p13 ) Anemia ( Hb &lt; 10g/dl ) Thrombocytopenia ( Plt &lt; 100000/mm3 ) Splenomegaly ( &gt; 5cm costal margin ) Extramedullary localization 4 . Patients untretaed previously treat Hydroxyurea Imatinib Etoposide give orally non intensive chemotherapy intensive chemotherapy give thann 3 month befor inclusion 5 . Performance Status ECOG 0,1 2 6 . Estimated life expectancy &gt; =6 month 7 . Adequate hepatic function : Total bilirubin &lt; 1.5 time upper limit normal ( except moderate unconjugate hyperbilirubinemia due intra medullary hemolysis ) AST ALT &lt; 3 time limit normal 8 . Adequate renal function : Serum creatinine &lt; 1.5 time limit normal Creatinine clearance &gt; 30ml/min 9 . Informed consent 10 . Negative pregnancy test adequate contraception method 1 . Myeloproliferative/myelodisplastic syndome othe CMML 2 . Acute blastic transformation CMML bone marrow blast cell &gt; 20 % 3 . Patients eligible allogenic bone marrow transplantation identify donor 4 . CMML ( 5 ; 12 ) PDGFBR rearrangement 5 . Intensive chemotherapy give less 3 month 6 . Previous treatment hypomethylating agent 7 . Age &lt; 18 year old 8 . Pregnancy breastfeed 9 . Performance Status ECOG &gt; 2 10 . Estimate life expectancy &lt; 6 month 11 . HIV infection 12 . Chronic active hepatitis secondary HCV HBV ( HBSAq positive ) 13 . Serious concomitantsystemic disorder , include active bacterial fungal viral infection , opinion investigator , would compromise safety patient and/or his/her ability complete study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Myelodysplastic Syndromes , Chronic Myelomonocytic Leukemia , Decitabine</keyword>
</DOC>